Medicine
Perioperative Management of Left Ventricular Assist Devices
Quick fact
LVADs can dramatically improve survival in end-stage heart failure, but up to 30% of patients develop right heart failure or significant bleeding in the first 30 days—making perioperative management as critical as the surgery itself.
Why this is interesting
Imagine your heart’s main pump is failing. A machine can take over its job—but only if you manage the transition perfectly. How do surgeons keep patients alive during this life-changing swap?
Read the full explanation
Understanding Perioperative Management of Left Ventricular Assist Devices
A left ventricular assist device (LVAD) is a mechanical pump that is implanted to help a weakened left ventricle push blood into the aorta and out to the body. Think of it as a booster pump placed in parallel with the heart’s main pump. During surgery, the LVAD is connected by a tube (cannula) that draws blood from the left ventricle and pushes it into the aorta. The device has a driveline (a cable) that exits through the skin and connects to an external controller and batteries. Perioperative management means the comprehensive care around this surgical procedure—before, during, and after. The goals are to keep the patient stable, ensure the device works correctly, and prevent complications. The surgery itself requires heart-lung bypass, like many open-heart operations. After implantation, the heart is 'unloaded'—the LVAD takes over much of the pumping work. This changes the pressure and flow throughout the heart, and the right side of the heart (which pumps blood to the lungs) suddenly has to handle increased blood return. Postoperatively, patients move to the intensive care unit (ICU). The team monitors hemodynamics—blood pressure, heart rate, and oxygen levels. They also manage anticoagulation: immediately after surgery, the risk of bleeding is high, so anticoagulants are usually withheld; once the patient is stable, they are started on anticoagulants to prevent blood clots forming in the pump. Infection control is crucial because the driveline site is a permanent entry point for bacteria.
A deeper explanation
The core mechanism underlying perioperative LVAD management is the abrupt change in cardiac loading conditions. The LVAD continuously unloads the left ventricle, reducing its work and wall stress. This increases systemic blood flow and perfusion, but it also increases venous return to the right ventricle (because the left side is no longer backing up blood into the lungs). If the right ventricle is already weak, it may fail under this increased preload, leading to a condition called right ventricular failure. To mitigate this, surgeons and intensivists use a combination of strategies: careful fluid management to avoid overloading the right ventricle, inotropic drugs to support right ventricular contraction, pulmonary vasodilators (like inhaled nitric oxide) to reduce the pressure the right ventricle must overcome, and sometimes temporary right ventricular assist devices. Another key mechanism is the balance between bleeding and clotting. The surgical procedure itself is extensive and involves anticoagulation during cardiopulmonary bypass. After surgery, the patient’s clotting system is deranged. Yet the LVAD is a foreign surface that activates platelets and clotting factors, posing a risk of thrombus formation inside the pump. Therefore, anticoagulation therapy (e.g., heparin, warfarin) is started once bleeding is controlled, and it is carefully monitored. Additionally, the driveline is a major infection risk. The skin entry site can allow bacteria to travel along the driveline to the pump, causing device infections, bacteremia, or sepsis. Protocols for sterile dressing changes and prompt treatment of infections are part of perioperative nursing and medical care. Why this matters: proper perioperative management directly impacts the success of the LVAD. Poorly managed patients suffer from early complications like right heart failure, bleeding, stroke from thrombosis, or infected devices, all of which increase mortality and reduce quality of life. A well-managed patient can leave the hospital and live months to years with the LVAD, either as a bridge to heart transplant or as destination therapy.